TY - JOUR
T1 - Optimizing MR-Guided Radiotherapy for Breast Cancer Patients
AU - Groot Koerkamp, Maureen L.
AU - Vasmel, Jeanine E.
AU - Russell, Nicola S.
AU - Shaitelman, Simona F.
AU - Anandadas, Carmel N.
AU - Currey, Adam
AU - Vesprini, Danny
AU - Keller, Brian M.
AU - De-Colle, Chiara
AU - Han, Kathy
AU - Braunstein, Lior Z.
AU - Mahmood, Faisal
AU - Lorenzen, Ebbe L.
AU - Philippens, Marielle E.P.
AU - Verkooijen, Helena M.
AU - Lagendijk, Jan J.W.
AU - Houweling, Antonetta C.
AU - van den Bongard, H. J.G.Desiree
AU - Kirby, Anna M.
AU - the Breast Tumor Site Group of the International MR-Linac Atlantic Consortium, Breast Tumor Site Group of the International MR-Linac Atlantic Consortium
N1 - Funding Information: Conflict of Interest: All authors are part of the Elekta MR-Linac Research Consortium. The aim of this consortium is to coordinate international research into the 1.5 T Elekta MR-linac. All authors have received financial support from Elekta for visiting consortium meetings. Elekta had no role in the preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. Publisher Copyright: © Copyright © 2020 Groot Koerkamp, Vasmel, Russell, Shaitelman, Anandadas, Currey, Vesprini, Keller, De-Colle, Han, Braunstein, Mahmood, Lorenzen, Philippens, Verkooijen, Lagendijk, Houweling, van den Bongard and Kirby.
PY - 2020/7/28
Y1 - 2020/7/28
N2 - Current research in radiotherapy (RT) for breast cancer is evaluating neoadjuvant as opposed to adjuvant partial breast irradiation (PBI) with the aim of reducing the volume of breast tissue irradiated and therefore the risk of late treatment-related toxicity. The development of magnetic resonance (MR)–guided RT, including dedicated MR-guided RT systems [hybrid machines combining an MR scanner with a linear accelerator (MR-linac) or 60Co sources], could potentially reduce the irradiated volume even further by improving tumour visibility before and during each RT treatment. In this position paper, we discuss MR guidance in relation to each step of the breast RT planning and treatment pathway, focusing on the application of MR-guided RT to neoadjuvant PBI.
AB - Current research in radiotherapy (RT) for breast cancer is evaluating neoadjuvant as opposed to adjuvant partial breast irradiation (PBI) with the aim of reducing the volume of breast tissue irradiated and therefore the risk of late treatment-related toxicity. The development of magnetic resonance (MR)–guided RT, including dedicated MR-guided RT systems [hybrid machines combining an MR scanner with a linear accelerator (MR-linac) or 60Co sources], could potentially reduce the irradiated volume even further by improving tumour visibility before and during each RT treatment. In this position paper, we discuss MR guidance in relation to each step of the breast RT planning and treatment pathway, focusing on the application of MR-guided RT to neoadjuvant PBI.
KW - MR-guided radiotherapy
KW - MR-linac
KW - breast cancer
KW - hybrid machine
KW - magnetic resonance imaging (MRI)
KW - neoadjuvant radiation therapy
KW - partial breast irradiation
UR - http://www.scopus.com/inward/record.url?scp=85089437841&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fonc.2020.01107
DO - https://doi.org/10.3389/fonc.2020.01107
M3 - Review article
SN - 2234-943X
VL - 10
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1107
ER -